News | August 24, 2023
Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ
The company has entered into a three-year Deferred Prosecution Agreement
The company has entered into a three-year Deferred Prosecution Agreement
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)